Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sage Therapeutic Com
(NQ:
SAGE
)
12.36
+0.07 (+0.57%)
Streaming Delayed Price
Updated: 12:07 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sage Therapeutic Com
< Previous
1
2
3
4
5
6
7
Next >
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
August 07, 2023
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with
Via
Benzinga
Wayfair To Rally Over 32%? Here Are 10 Other Analyst Forecasts For Monday
August 07, 2023
Needham raised the price target for MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) from $65 to $84. Needham analyst Quinn Bolton maintained a Buy rating. MACOM Technology shares rose 0.1% to...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 31, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Sage Therapeutics
July 27, 2023
Via
Benzinga
Why Sage Therapeutics Stock Is Tumbling Today
July 26, 2023
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.
Via
The Motley Fool
Expert Ratings for Sage Therapeutics
May 09, 2023
Via
Benzinga
Sage Therapeutics's Earnings Outlook
May 01, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Sage Therapeutics
March 09, 2023
Via
Benzinga
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 26, 2023
Via
Benzinga
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
March 13, 2023
Via
Benzinga
Expert Ratings for Sage Therapeutics
December 06, 2022
Via
Benzinga
Sage Therapeutics's Return On Capital Employed Insights
December 05, 2022
Via
Benzinga
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
October 17, 2022
Via
Benzinga
Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 26, 2023
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
March 13, 2023
Via
Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Via
Benzinga
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
March 13, 2023
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Sage Therapeutics: Q2 Earnings Insights
August 02, 2022
Sage Therapeutics (NASDAQ:SAGE) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Where Sage Therapeutics Stands With Analysts
July 11, 2022
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Via
Benzinga
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
February 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
September 09, 2022
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.
Via
Investor's Business Daily
8 Analysts Have This to Say About Sage Therapeutics
May 24, 2022
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Via
Benzinga
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
August 11, 2022
Today's depression drugs don't fit many patients' needs. Biotech companies may change that.
Via
Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
June 01, 2022
Sage and Biogen say their MDD drug met every goal in a study of postpartum women.
Via
Investor's Business Daily
Analyst Ratings for Sage Therapeutics
May 04, 2022
Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Earnings Scheduled For August 2, 2022
August 02, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.